Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Lonza Group Ltd.
Industry Sector: HealthTechnology
CEO: Wolfgang Wienand, PhD
Number Of Employees: 18,686
Enterprise Value: $46,174,678,012
PE Ratio: 56.02
Exchange/Ticker 1: SIX:LONN
Exchange/Ticker 2: N/A
Latest Market Cap: $42,030,587,031
BioCentury | Apr 3, 2025
Product Development
Exosomes are finding new life as the field solves for manufacturing
Can exosomes step in as delivery vehicles where LNPs fall short?
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Oct 29, 2024
Emerging Company Profile
Kivu: Advancing safer ADCs against established targets
Company launches with $92 million to develop antibody-drug conjugates spun out of Synaffix
BioCentury | Sep 12, 2024
Regulation
Industry calls on FDA to clarify, expand platform tech program
Comments on the agency’s guidance document include requests that it extend the designation to platforms that have yet to yield an approved drug
BioCentury | Apr 3, 2024
Management Tracks
Takeda vet Tanigaki named CEO of Aculys
Plus: Lonza names Wolfgang Wienand CEO, and updates from Verily, GSK, NewAmsterdam, Voyager, Adaptive, Ratio, Adlai Nortye and I-Mab
BioCentury | Mar 15, 2024
Finance
WuXi shares take a hit as BIO reverses position on anti-China legislation
Market caps of WuXi AppTec, WuXi Bioloics has dropped over 40% since mid-January
BioCentury | Feb 21, 2024
Politics, Policy & Law
Hearing on anti-China bills back on amid continued pressure on WuXi stocks
As WuXi stocks tumble, shares of ex-China CDMOs rise
BioCentury | Sep 20, 2023
Management Tracks
Orwin succeeds Topper as AnaptysBio’s chair
Plus: CDMOs Catalent and Rentschler announce executive changes, and updates from Parexel, Santander, CorriXR and more
BioCentury | Sep 18, 2023
Management Tracks
Peter Bains named group CEO at Biocon
Plus: CEO changes at Lonza and Black Diamond, and updates from ImmunoGen, BenevolentAI and Nilogen
BioCentury | Sep 14, 2023
Management Tracks
DNAnexus names Laur as CEO
Plus: Ports now CSO at Cargo and updates from Protalix, Culture, 4D, DiaMedica, Likarda, Precise, Pixelgen and Oviva
Items per page:
1 - 10 of 138